135 related articles for article (PubMed ID: 28992168)
1. Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials.
Humbert M; Singh M; Furst DE; Khanna D; Seibold JR
Rheumatology (Oxford); 2017 Sep; 56(suppl_5):v33-v37. PubMed ID: 28992168
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme.
Morrisroe K; Stevens W; Sahhar J; Rabusa C; Nikpour M; Proudman S;
Arthritis Res Ther; 2017 Mar; 19(1):42. PubMed ID: 28270192
[TBL] [Abstract][Full Text] [Related]
3. New trial designs and potential therapies for pulmonary artery hypertension.
Gomberg-Maitland M; Bull TM; Saggar R; Barst RJ; Elgazayerly A; Fleming TR; Grimminger F; Rainisio M; Stewart DJ; Stockbridge N; Ventura C; Ghofrani AH; Rubin LJ
J Am Coll Cardiol; 2013 Dec; 62(25 Suppl):D82-91. PubMed ID: 24355645
[TBL] [Abstract][Full Text] [Related]
4. A review of ongoing trials in exercise based rehabilitation for pulmonary arterial hypertension.
Babu AS; Padmakumar R; Maiya AG
Indian J Med Res; 2013 May; 137(5):900-6. PubMed ID: 23760374
[TBL] [Abstract][Full Text] [Related]
5. From short-term benefits to long-term outcomes: the evolution of clinical trials in pulmonary arterial hypertension.
Chakinala MM; Barst R
Pulm Circ; 2013 Sep; 3(3):507-22. PubMed ID: 24618537
[TBL] [Abstract][Full Text] [Related]
6. One year in review 2017: systemic sclerosis.
Barsotti S; Bruni C; Orlandi M; Della Rossa A; Marasco E; Codullo V; Guiducci S
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):3-20. PubMed ID: 29035173
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort.
Mihai C; Antic M; Dobrota R; Bonderman D; Chadha-Boreham H; Coghlan JG; Denton CP; Doelberg M; Grünig E; Khanna D; McLaughlin VV; Müller-Ladner U; Pope JE; Rosenberg DM; Seibold JR; Vonk MC; Distler O
Ann Rheum Dis; 2018 Jan; 77(1):128-132. PubMed ID: 29061853
[TBL] [Abstract][Full Text] [Related]
8. Assessment of skin involvement in systemic sclerosis.
Kumánovics G; Péntek M; Bae S; Opris D; Khanna D; Furst DE; Czirják L
Rheumatology (Oxford); 2017 Sep; 56(suppl_5):v53-v66. PubMed ID: 28992173
[TBL] [Abstract][Full Text] [Related]
9. Points to consider-Raynaud's phenomenon in systemic sclerosis.
Cutolo M; Smith V; Furst DE; Khanna D; Herrick AL
Rheumatology (Oxford); 2017 Sep; 56(suppl_5):v45-v48. PubMed ID: 28992170
[TBL] [Abstract][Full Text] [Related]
10. Points to consider in renal involvement in systemic sclerosis.
Galluccio F; Müller-Ladner U; Furst DE; Khanna D; Matucci-Cerinic M
Rheumatology (Oxford); 2017 Sep; 56(suppl_5):v49-v52. PubMed ID: 28992172
[TBL] [Abstract][Full Text] [Related]
11. An Update on Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: a Review of the Current Literature.
Sundaram SM; Chung L
Curr Rheumatol Rep; 2018 Feb; 20(2):10. PubMed ID: 29488016
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary arterial hypertension associated with connective tissue diseases: A review focusing on distinctive clinical aspects.
Kato M; Atsumi T
Eur J Clin Invest; 2018 Feb; 48(2):. PubMed ID: 29285766
[TBL] [Abstract][Full Text] [Related]
13. Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension.
Furukawa A; Tamura Y; Iwahori H; Goto M; Ohashi N; Okabe T; Kawamura A
BMC Pulm Med; 2017 Oct; 17(1):135. PubMed ID: 29073911
[TBL] [Abstract][Full Text] [Related]
14. Interstitial lung disease points to consider for clinical trials in systemic sclerosis.
Khanna D; Seibold J; Goldin J; Tashkin DP; Furst DE; Wells A
Rheumatology (Oxford); 2017 Sep; 56(suppl_5):v27-v32. PubMed ID: 28992174
[TBL] [Abstract][Full Text] [Related]
15. Points to consider for skin ulcers in systemic sclerosis.
Galluccio F; Allanore Y; Czirjak L; Furst DE; Khanna D; Matucci-Cerinic M
Rheumatology (Oxford); 2017 Sep; 56(suppl_5):v67-v71. PubMed ID: 28992171
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis.
Ueda T; Sakagami T; Kikuchi T; Takada T
Respir Investig; 2018 Jan; 56(1):14-20. PubMed ID: 29325675
[TBL] [Abstract][Full Text] [Related]
17. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group.
Sánchez-Cano D; Ortego-Centeno N; Callejas JL; Fonollosa Plá V; Ríos-Fernández R; Tolosa-Vilella C; Espinosa-Garriga G; Colunga-Argüelles D; Egurbide-Arberas MV; Rubio-Rivas M; Freire M; Ríos-Blanco JJ; Trapiella-Martínez L; Rodríguez-Carballeira M; Marín-Ballvé A; Pla-Salas X; Simeón-Aznar CP
Rheumatol Int; 2018 Mar; 38(3):363-374. PubMed ID: 29322341
[TBL] [Abstract][Full Text] [Related]
18. 2013 ACR/EULAR systemic sclerosis classification criteria in patients with associated pulmonary arterial hypertension.
Joven BE; Escribano P; Andreu JL; Loza E; Jimenez C; de Yebenes MJG; Ruiz-Cano MJ; Carmona L; Carreira PE
Semin Arthritis Rheum; 2018 Jun; 47(6):870-876. PubMed ID: 29126717
[TBL] [Abstract][Full Text] [Related]
19. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI
Preston IR; Channick RN; Chin K; Di Scala L; Farber HW; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF; Rubin LJ
J Heart Lung Transplant; 2018 Mar; 37(3):401-408. PubMed ID: 29096938
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
